-
Chiasma Plunges 60% Following FDA Review, CEO 'Surprised, Disappointed And Respectfully Disagree With The Decision'
Monday, April 18, 2016 - 10:34am | 354Read More...Shares of Chiasma Inc (NASDAQ: CHMA) plunged more than 60 percent Monday morning after the company provided an update regarding its New Drug Application for Mycapssa capsules. Chiasma is a biopharmaceutical company that focuses on treating patients with rare and serious chronic diseases. Its...
